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1. Introduction 
Various brain injuries in humans such as neurotrauma,stroke, infection, febrile convulsions 
and status epilepticus are associated with the acute occurrence of seizures and an increased 
risk of developing epilepsy, Experimental studies in rodents have shown that these events 
induce a chronic decreased seizure threshold or the development of spontaneous seizures, 
supporting the notion, that central nervous system (CNS) injury can lead to lasting 
hyperexcitability. These injuries trigger inflammatory processes in the brain, which are 
rapidly ensuing and long-lasting, raising the possibility that inflammatory mediators may 
contribute to the development of epileptogenesis, and the consequent precipitation of 
spontaneous seizures. 
On the other hand a pathogenic role of immunity in epilepsies has long been suggested 
based on observations of the efficacy of immune-modulating treatments and, more recently, 
by the finding of inflammation markers including autoantibodies in individuals with a 
number of epileptic disorders. Clinical and experimental data suggest that both innate and 
adaptive immunity may be involved in epilepsy. Innate immunity represents an immediate, 
nonspecific host response against pathogens via activation of resident brain immune cells 
and inflammatory mediators. These are thought to contribute to seizures and 
epileptogenesis. Adaptive immunity employs activation of antigen specific B and T 
lymphocytes or antibodies in the context of viral infections and autoimmune disorders.  
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This review focused first on the description of the interaction between the immune system 
and CNS peculiar aspects and relevance for the pathogenesis of immune–mediated diseases 
of the CNS, second, we offer an overview of the experimental evidence in experimental 
models of seizures to discuss how inflammation modulates epilepsy, and whether 
inflammation is always detrimental to cell survival. Such research has also sought to 
determine how inflammatory mechanisms might be harnessed to develop therapies for 
epilepsy and third we describe causal clinical evidences of various forms of human epilepsy 
in which CNS inflammation and markers of adaptive immunity have been described, also 
we describe some of the treatments used in pharmacoresistan epilepsy with probable 
autoimmune origin. 
2. Overview of the immune system 
The natural defences presented by an individual to any external agent are included in the 
immune system; this is generally divided into innate and adaptive immunity. Innate 
immunity is the first response presented against insult, that is triggered by physical, 
chemical or bacteriological damage, the latter is the most familiar and easier to reproduce by 
introducing systemic lipopolysaccharide or LPS, which is the substance that covers the outer 
membrane of Gram (-)bacteria (Condie, 1955; Rivest , 2000). For its study, innate immunity 
is divided into the afferent arm, which identifies or perceives to insult, and the efferent arm, 
which is how the infection is eradicated (Tracey, 2009). Several studies have shown that 
depending on the agent causing the damage, pathway, organ and even insult cells triggers a 
series of molecules for defence of the individual and the communication between immune 
system cells can lead to out both by direct contact between cells or by the involvement of 
soluble factors known as cytokines. This will differentiate the humoral components of the 
afferent arm (LBP, CD14, collectins, properdin, C3b, pentraxins) and efferent (cytokines, 
antimicrobial peptides, lysozyme, BPI, complement, lactoferrin, acute phase reactants) and 
cellular components of the afferent arm (TLRs, dectina-1, CD14, formyl peptide receptor or 
FMLP, NOD1, NOD2) and efferent (antimicrobial peptides, proteases, lipases, glycosidases, 
cell adhesion molecules, H2O2, hydroxyl radical, oxygen halides, nitric oxide, peroxynitrite, 
etc.) (Beutler, 2004; Vezzani, 2005). 
Until recently, adaptive immunity was considered a type of immune response independent 
of the innate immune response; now it is known that both responses are intertwined, so the 
participation of dendritic cells, monocytes, macrophages, B lymphocytes and T, specialized 
molecules of immune histocompatibility, complex class I and II (MHC I and II) that are 
present during the innate response, are the beginning of the adaptive response (Iwasaki, 
2010). In this type of response antigen recognition is carried by the specific antigen-
presenting cells (APCs) and antigen receptors. In the adaptive immune response; it is 
identified two ways: the conventional adaptive immunity in jawed vertebrates and 
unconventional characteristic of jawless vertebrates.  
The first is mediated by immunoglobulins (Ig) and T cell receptors (TCRs) (Fig 1). Low-
affinity IgM antibodies circulate in the blood prior to encountering pathogens, however, 
high-affinity IgG and IgA antibodies are required to inactivate toxins, neutralize viruses, 
and promote the clearance of microorganisms (Li, 2004). Prior to antigen exposure, the 
initial generation of a diverse antibody repertoire is achieved early in B-lymphocyte 
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development by the successful rearrangement of the V, D, and J gene. This recombination 
process depends on the recognition of recombination signal sequences (RSSs), which flank 
the segmental elements and create extensive variation in the receptor structure at 
junctional (joining) interfaces. V(D)J rearrangement form of somatic recombination occurs 
in the progenitors of B and T cells and is mediated by recombination-activating gene 1 
(RAG1) and RAG2, which function in a lymphocyte- and site-specific recombinase 
complex and are supported by ubiquitous DNA repair factors (Fig 1A)(Gellert, 2002). The 
Immunoglobulins function first as membrane-bound receptors on B cells and their 
precursor cells, and they are selected for both antigen-binding specificity and affinity. A 
change in RNA splicing converts the membrane-bound receptor to a soluble product and 
is associated with the differentiation from receptor-expressing B cells to immunoglobulin-
secreting plasma cells. A second wave of antibody diversification occurs through somatic 
hypermutation (SHM) (Fig. 1B) and/or gene conversion (GC) of the V region to generate 
high-affinity antigen binding sites (MacLennan, 1994). SHM is the predominant 
mechanism in mice and humans, whereas GC occurs in chickens and some other species 
(Weill and Reynaud 1996). In the same centroblast B cell, the heavy-chain V regions 
encoding the antigen binding sites are rearranged down the chromosome through class 
switch recombination (CSR) so that they can be expressed with one of the constant (C) 
region genes to carry out many different effector functions and be distributed throughout 
the body (Fig. 1C). Activation-induced cytidine deaminase (AID) mediates SHM, gene 
conversion and class-switch recombination (CSR). 
The TCR is a clonotypic, membrane-bound receptor that binds peptide-MHC (pMHC). 
Similar to immunoglobulins, both classes of TCRs (ǂǃ TCRs and Ǆǅ TCRs) are heterodimers 
in which a D segment is a rearranging component of one unit of the receptor heterodimer. 
The function of ǂǃ TCRs relies on the polymorphic MHC class I and class II molecules 
expressed by antigen-presenting cells. By contrast, Ǆǅ TCRs function independently of MHC 
class I and class II molecules and it has been proposed that a forerunner of the rearranging 
antigen-binding receptors might have been a Ǆǅ TCR-like receptor (--12--). Genetically, TCRs 
are rearranged into  and -chains from a selection of 176 variable (V), diversity (D), joining 
(J), and constant (C) genes on chromosomes 7 and 14. Random recombination of these genes 
generates only 5–10% of the potential diversity within the TCR repertoire; exonucleolytic 
activity, random N nucleotide additions at the V(D)J junctions (Cabaniols, 2001) and  
chain pairing contribute the remainder (Fig 1). Theoretical TCR diversity in humans has 
been placed in the region of 1015 - 1020 unique structures (Davis, 1988; Lieber 1991; Shortman, 
1990), with direct in vivo estimates greater than 2.5X107 unique structures (Arstila, 1999). 
Structurally, TCR - and -chains fold to expose six highly flexible complementary 
determining region (CDR) loops that can contact the pMHC binding face. The germline-
encoded CDR1 and CDR2 loops, from the TRAV and TRBV genes, participate heavily in 
MHC contacts and occasionally peptide contacts. The variable CDR3 loops, which span the 
V(D)J joints, are key to TCR diversity and participate heavily in peptide contacts. TCRs dock 
with pMHC complexes in a roughly diagonal fashion, such that the CDR3 loops are placed 
over the peptide N-terminus and the CDR3 loops lie over the peptide C-terminus (Miles, 
2010). 
In unconventional adaptive immunity, the specific response to antigens of bacteria and 
blood cells is similar to cellular immunity and identified lymphocyte-like cells in organs 
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and tissues (Alder, 2005). On the other hand humoral mediators are somatically derived 
variants of leucine-rich repeats or LRRs, termed variable lymphocyte receptors (VLRs), 
which are as efficient as V (D) J process. The mechanism of VLRs assembly seems to be 
driven by a copy choice mechanism of recombination that is based on sequence 
similarities of individual LRR segments rather than by specific recombination elements 
(Han, 2008; Nagawa, 2007). 
Although immunoglobulins, TCRs, and VLRs are structurally unrelated and somatic 
variations generated through unrelated mechanisms, these molecules develop clonal 
specificity through somatic recombination, show evidence of specific cell lineage 
compartmentalization in receptor expression and can share common features in the 
recipient's immune regulation (Litman, 2010). 
3. Immunology of the nervous system 
The CNS has developed strategies to limit the entry of immune elements as well as to 
limit the emergence of immune activation with the tissue itself. Immune privilege in the 
CNS is partially dependent on the blood–brain barrier (BBB), which is designed to limit 
the entry of solutes and ions into the CNS(Carson et al.,2006). Exclusion from, and 
selective entry of compounds into the CNS takes place in the capillary venules. In contrast 
,cell migration takes place at the post-capillary venules, where cell migration is controlled 
by adhesion molecules, cytokines and chemokines, and their receptors (Fig.2)(Owens et 
al., 2008). Not only the physical properties of the BBB, but also potentially damaging 
immune responses as such are regulated by the suppressive environment within the CNS. 
Both astrocytes and microglia play a major role in this regulation, while neurons are 
assumed to play a largely passive role being only the victims of immune responses. 
Microglia invade the brain early in development and take on a resting ‘protective’ role as 
sentinels, scattered uniformly throughout the CNS and forming a network of potential 
effectors cells. In contrast to peripheral macrophages that are highly effective at inciting 
pro-inflammatory responses, microglia take on an opposing role, limiting inflammation. 
This role is extended also to astrocytes, the first cells that CNS-infiltrating immune cells 
encounter. Astrocytes suppress T helper 1 (Th1) and T helper 2 (Th2) cell activation, the 
proliferation and effector functions of activated T cells, and possess a wide variety of 
molecular mechanisms to induce apoptosis in activated T cells. Contrary to the idea that 
neurons only play a passive role, many of their products (i.e. neuropeptides and 
transmitters), as well as the neuronal membrane proteins CD22, CD47, CD200, CX3CL1 
(fractalkine), intercellular adhesion molecule (ICAM), neural cell adhesion molecule 
(NCAM), semaphorins and C-type lectins all regulate inflammation (Tian, 2009). In 
addition, neurons express low levels of major histocompatibility complex (MHC) 
molecules and actively promote T-cell apoptosis via the Fas–Fas ligand pathway (CD95–
CD95L). Neuronal expression of the cannabinoid (CB1) receptor is also implicated in 
suppressing inflammation. CB1 knockout mice more readily develop experimental 
autoimmune encephalomyelitis (EAE), the autoimmune model of multiple sclerosis (MS). 
Neurons also favour the differentiation of T-regulatory cells, by providing a local 
microenvironment dominated by transforming growth factor–b1 (TGF-b1). Damaged 
neurons, however, are less able to maintain this protective shield, allowing further  
insults.  
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Fig 1. Conventional adaptative immune response in jawed vertebrates. A haematopoietic 
progenitor cell gives rise to distinct B and T cell lineages. During the development of Ig and 
TCR different recombination processes are involved. A) V(D)J recombination. In this process, 
RSSs (dark and white triangles) direct the RAG1–RAG2 recombinase complex to individual 
gene segments (dark and white boxes). The recombinase introduces two double-strand DNA 
breaks with blunt signal ends and hairpin-sealed coding ends. In the subsequent joining phase, 
TdT a template-independent DNA polymerase, adds random nucleotides to the junction of the 
gene elements, thereby increasing repertoire diversity dramatically; the RSSs are joined 
without further end processing and form excision circles. The key factors that facilitate each 
diversification step are NHEJ factors. Once functional DNA rearrangements occur, TCR 
sequences are unaltered. B) Somatic hypermutation is initiated by AID, which deaminates 
individual cytidines within the V(D)J exon of the immunoglobulin gene, leading to U:G 
mismatches (asterisk). Subsequent error-prone repair results in individual point mutations 
(white dot in the gene and white bar in the immunoglobulin molecules), and B cells with 
higher affinity for the original antigen are selected. C) Class-switch recombination. The AID 
creates U:G mismatches in the highly repetitive S regions (dark and white ovals) that are 
upstream of the exons encoding the constant regions of different isotypes. Error-prone repair 
leads to the generation of double-strand DNA breaks, excision of the intervening DNA 
(containing the Cμ exons) and joining of the remains of the S regions. The recombined, 
somatically mutated V(D)J region is then associated with CǄ, instead of Cμ. ( Modified from 
Litman, 2010). B and T cell lineages. Immunoglobulin heavy and light chain: IgH and IgL; T 
cell receptor ǂ and  chain: TCRǂ and TCRǃ. A) V(D)J recombination. Variable, diversity, 
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joining genes: V(D)J; Recombination signal sequences: RSSs; Recombination activating gene 1 
and 2: RAG1 and RAG2; Terminal deoxynucleotidyl transferase: TdT; Non-homologous end-
joining: NHEJ. B) Somatic hypermutation. Activation-induced cytidine deaminase: AID. C) 
Class-switch recombination. Switch (S); Constant region for the Igμ isotype (Cμ) and a single 
representative downstream CǄ exon within the IgH locus. 
4. Innate and adaptive responses in epilepsy 
Despite the immune-privileged environment, it is clear that both innate and adaptive 
inflammatory responses do occur in the CNS. Activation of the innate immune system is a 
crucial first line of defense, to opsonize and clear apoptotic cells. Furthermore, innate 
immune responses recruit cells of the adaptive immune system by secreting various 
cytokines and chemokines that induce adhesion molecules on the BBB, and by inducing the 
expression of costimulatory molecules on microglia. Through conserved pattern-recognition 
receptors (PRRs), local CNS cells may be triggered to develop innate responses. Among 
these receptors are Toll-like receptors (TLRs), which bind highly conserved structural motifs 
either from pathogens (pathogen-associated molecular patterns, or PAMPs) or from 
damaged or stressed tissues (danger-associated molecular patterns, or DAMPs). Thus, not 
only invading micro-organisms, but also endogenous signals can switch on innate responses 
in the CNS. Some DAMPs, including heat shock proteins, uric acid, chromatin, adenosine 
and ATP, high mobility group box chromosomal protein 1 (HMGB-1), galectins and 
thioredoxin have adjuvant and pro-inflammatory activity. TLRs can be widely up-regulated 
during neurological disorders in varying patterns on microglia, astrocytes, oligodendrocytes  
and neurons (Bsibsi, 2002). When activated, TLRs are generally assumed to promote the 
production of pro-inflammatory cytokines, evoking a damaging environment that may 
contribute to neuronal damage. In vitro, Ab activates microglia through TLRs (Jackson et al., 
2006, Okun et al., 2009;Letiembre et al.,2009). TLRs also aid the uptake of Ab and other 
aggregated proteins, thereby promoting their clearance from the CNS. Although in this 
manner, TLRs may seem to play a beneficial role in epilepsy it is currently unclear whether 
cellular activation by TLRs in another way may also contribute to epileptogenesis (Ravizza 
et al., 2011 ) . Therefore, rather than only playing a pathogenic role, several TLRs also play a 
role in repair during neurodegenerative disorders, under non-infectious conditions, 
suggesting that activation of at least some TLRs can also be used as a therapeutic strategy in 
CNS disorders(van Noort, 2007) 
4.1 Experimental evidence   
Due to advances in both structural and functional neuroimaging, as well as opportunities to 
perform invasive investigations of the human brain in an epilepsy surgery setting, an 
increasing amount of research on focal epilepsy is now utilizing patients and tissue obtained 
from patients. Nevertheless, parallel studies on patients and well validated equivalent 
animal models remain indispensable to circumvent difficulties in clinical research resulting 
from ethical limitations, cost, inadequate sampling, and absence of appropriate controls. The 
reliability of animal models in analysing epileptogenic mechanisms and testing the efficacy 
of antiepileptic drugs (AEDs) depends on how faithfully the epileptic phenomenology 
mimics both the clinical and EEG features of human seizures. Moreover, since human 
epilepsies are defined as pathological conditions characterized by the recurrence of epileptic  
www.intechopen.com
 
Adaptive Immune Response in Epilepsy 
 
141 
 
Fig. 2. T cell migration through the BBB in epilepsy. T-cell can enter the brain parenchyma 
by extravasation  across the blood–brain barrier nonfenestrated endothelium and basal 
lamina. Antigen-presenting cells such as dendritic cells and macrophages are found in the 
subarachnoid space, in the perivascular space, and in the choroid plexus, whereas microglia 
are located in brain parenchyma; at these locations, these cells may encounter circulating 
CNS-borne antigens. The abnormal permeation across the barrier results in further, and 
perhaps distal, disruption of tight junctions, this time mediated by release of inflammatory 
mediators by both extravasated blood cells and activated microglia. Frank cellular 
immunoagression occurs if and when histocompatibility mechanisms are activated and 
antibody-mediated reactions occur. IL, interleukin; TNF, tumor necrosis factor; IFN, 
interferon; CSF, colony-stimulating factor; MHC, major histocompatibility complex, modify 
by Mix et al (2007) and Oby and Janigro (2006). 
seizures only animals presenting with recurrent seizures can be defined as animal models 
of epilepsy. The acute experimental procedures designed to induce seizures, such as the 
injection of convulsant drugs, maximal electroshock etc., should therefore be referred to 
as animal models of seizures and not epilepsies unless they also induce a permanent 
epileptogenic. In this way the models have been described  as acute experimental seizure 
models, in which seizures are induced by electrical stimulation, topical convulsants that 
block inhibition (e.g., penicillin, bicuculline, picrotoxina, pentylenetetrazol, strychnine), or 
topical convulsants that enhance excitation (e.g., carbachol, kainic acid). Chronic models 
of focal epilepsy can be induced with freeze lesions, partially isolated cortical slabs, 
metals (e.g., alumina, cobalt, tungstic acid, ferric chloride), kindling, tetanus toxin, anti-
GM1 ganglioside antibodies, hippocampal sclerosis (kainic acid, pilocarpine, self-
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sustained status epilepticus), or focal dysplasia (neonatal freeze, prenatal radiation, 
MAM) (Engel, 2004). 
Some of these epilepsy models in rodents trigger a prominent inflammatory response in 
brain regions recruited in the onset and propagation of epileptic activity; depending on the 
severity of the seizures, the inflammatory activity is affected in different ways (Minami, 
1990;1991; Gahring, 1991;Jankowsky &Patterson, 2001; Kubera,2001; Oprica,2003; 
Turrin,2004). In models of temporal lobe epilepsy, the seizures produce changes in the 
function of the peripheral immune system. The thymus, for example, displays reduced 
weight, probably due to elevated corticosterone plasma levels during kainate-induced 
seizure; this steroid is induced during some kinds of stress or after a pathogenic infection. 
An increase in metabolic activity of splenocytes at the cellular level may be connected to 
enhanced phagocytic activity of macrophages (Kubera et al., 2001). The inflammatory 
response occurs during the 3 days following seizures. Although IL-1┚, TNF-┙, and IL-6 are 
expressed at very low levels in normal brain, their messenger RNA (mRNA) and protein 
levels are rapidly (≤30 min) increased after the induction of seizures, declining to basal 
levels within 48–72 h from the onset of seizures. However, IL-1ǃ is still up regulated in the 
brain 60 days after status epilepticus in rats with spontaneous seizures (Plata et al., 2000). 
The increase in interleukin (IL)-1ǃ, IL-6 and TNF-ǂ in microglia and astrocytes is followed 
by a cascade of downstream inflammatory events which may recruit cells of the adaptive 
immune system ( Vezzani and Granata, 2005). 
The kindled model exhibited a significant up-regulation of IL-1 ǃ, IL-1RI, TNF-┙ and TGF-┚1 
mRNAs in several limbic brain regions. The overall profile of mRNA changes shows 
specificity of transcriptional modulation induced by amygdala kindling. The data support a 
role for cytokines and NPY in the adaptive mechanisms associated with generalized seizure 
activity (Gahring, 1997). Cytokine production is also induced in brain by audiogenic 
seizures(Lee, 2008). Production of proinflammatory molecules (a cytokine induced portfolio 
of genes that are established mediators of inflammation (Dinarello, 2000) is typically 
accompanied by the concomitant synthesis of anti-inflammatory mediators and binding 
proteins apt to modulate the inflammatory response, thus avoiding the occurrence of 
deleterious induction of genes that mediate inflammatory effects. In this respect, up 
regulation of IL-1–receptor antagonist (Ra), a naturally occurring antagonist of IL-1ǃ, has 
been described after acute seizures, status epilepticus, and in kindling (Gasque ,1997; Gorter, 
2006;Avignone ,2008). However, IL-1Ra and IL-1ǃ are induced by seizures and IL-1Ra is 
produced with a delayed time course, differing from classic inflammatory reactions in 
which IL-1Ra is produced at 100- to 1,000-fold excess and concomitant with IL-1ǃ 
production. Thus the brain is less effective than the periphery in inducing a crucial 
mechanism for rapidly terminating the actions of a sustained increase in endogenous IL-1ǃ. 
Cytokine receptors in the CNS are expressed by neurons, microglia, and astrocytes. 
However, it is primarily microglia activation that has morphologic changes related to the 
seizures and inflammation; this is a complex process that includes changes in 
pharmacological and electrophysiological properties, migration, proliferation, and release of 
a variety of mediators. In the context of status epilepticus induced by kainate, microglia are 
activated within the same time course that is observed for neuronal degeneration 
(Hosokawa, 2003; Xiong,2003).  
The immune response changes during all three phases of epileptogenesis. The genes related 
to immune response are induced during both acute and latent phases of epileptogenesis but 
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also during the chronic phase (in CA3).  Although the immune response was greater one 
week after status epilepticus, the levels of secreted phosphoprotein 1 (Spp1 or osteopontin), 
a glycoprotein that promotes macrophage migration, Hg2a (or CD74; H-2 class II 
histocompatibility antigen), proteasomes (Psmb9, macropain), toll-like receptor 4 (Tlr4), and 
tumor necrosis factor (Gorter,2006), also, the prostaglandin synthesis, illustrated by Cox-2 
induction, was activated in the acute and chronic phases but not in the latent period, 
indicating that this process is related to the occurrence of seizure activity. Activation of 
prostaglandin receptors could increase intracellular calcium and subsequent glutamate 
release, which would increase excitability in the surrounding networks (Bezzi et al., 1998; 
Rozovsk et al.,1994)   
An important component of the immune response is activation of the complement pathway. 
Although complement factors might invade the brain via a leaky BBB, part of the increased 
expression is likely to originate from activated glial cells (Ravizza et al., 2006;Vezzani, 2008). 
The complement system may be useful for eliminating aggregated and toxic proteins. 
However, overactivation of the complement system can also have damaging effects through 
the activation of microglia and proinflammatory cytokines. Interestingly, sequential infusion 
of individual proteins of the membrane attack pathway into the hippocampus of freely 
moving rats induces seizures as well as cytotoxicity (Ravizza et al., 2006). 
The complement cascade is activated by three pathways: the classical, the alternative, and 
the lectin pathway; the lectin pathway leads to the formation of the C5b-C9 membrane 
attack protein complex (MAC). Complement activation in the CNS is increasingly 
recognized to be associated with exacerbation and progression of tissue injury in different 
degenerative and inflammatory diseases. Interestingly, sequential infusion of individual 
proteins of the membrane attack pathway (C5b6, C7, C8, and C9) into the hippocampus of 
awake, freely moving rats induces both behavioral and electrographic seizures as well as 
cytotoxicity, suggesting a role for the complement system in epileptogenesis. Rozowski and 
colleagues (1994) showed increased C1q and C4 mRNA in rat pyramidal neurons after 
systemic injection of convulsant doses of kainic acid in neuronal layers of limbic areas that 
are vulnerable to kainic acid-induced neurodegeneration (Vezzani, 2008); moreover, 
clusterin and C1q immunoreactivities were observed in both neurons and astrocytes, while 
increased immunoreactivities (as observed in vivo after seizures) were demonstrated 
following prolonged exposure of primary cultures of hippocampal neurons to glutamate. 
Additionally, with sequential infusion into the rat hippocampus the individual proteins of 
the MAC induced both behavioral and electrographic seizures as well as cytotoxicity 
(Ravizza et al, 2006).  
In addition, there is prominent activation of the complement cascade during the 
epileptogenesis phase in the experimental model and in sclerotic hippocampi from a rat 
model of TLE and human TLE (Aronica et al., 2007). Interestingly, the expression of CD59, a 
complement inhibitor of the MAC, was increased in microglia, but only modestly in 
neurons, suggesting that in this cell population complement activation may be poorly 
controlled (Rozovsky et al., 1994). These findings are corroborated by clinical evidence 
showing that both IL-1ǃ and IL-1 receptor type I (RI), NFkB and complex are overexpressed 
in lesional brain tissue of patients with diverse types of pharmacoresistant epilepsy (Sheng 
et al., 1994, Crespel et al., 2002) 
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4.2 Clinical evidence 
From a clinical standpoint, a role of inflammation in the pathophysiology of human epilepsy 
is still hypothetical, although this possibility is supported by abundant evidence. The first 
insight into a role for inflammation in epilepsy originated from the demonstrated 
antiepileptic activity of select, powerful anti-inflammatory drugs, including steroids. 
Moreover, several reports showed increased markers of inflammation in serum, CSF, and 
brain resident cells in patients with epilepsy. For example, epileptic patients who have 
recently experienced tonic–clonic seizures display a proinflammatory profile of cytokines in 
plasma and CSF, consisting of higher IL-6 levels and a lower IL-1Ra–to–IL-1ǂ ratio. Because 
the IL-6 concentration is much higher in CSF than in plasma (Pacifici et al., 1995; Peltola et 
al., ,1998) and the contribution of peripheral blood mononuclear cells (PBMCs) to increased 
plasma levels of cytokines is still unclear (Sheng et al., 1994), the most likely origin of CSF 
cytokines appears to be the brain. In the same way, Sinha et al. (2008) analyzed cytokine 
levels in patients with partial epilepsy, status epilepticus and some epilepsy syndromes. 
Compared to controls, the patient group showed detectable levels of the following cytokines 
in serum: IL-6, TNF-, IL-2, IL-4, IFN- and IL-1. Serial analysis during the seizure-free 
period revealed a decrease in cytokine levels: TNF- (25% to 12.5%), IFN- (12.5%to 0%), IL-
1 (25% to 0) and IL-2 (6.2% to 6.2%), IL-4 (18.8% to 0%) and IL-6 (18.8% to 6.2%). On the 
other hand, increased post-ictal serum cytokine levels were found in patients with several 
epilepsy syndromes. However, data collected using tissue of patients with TLE show that 
specific inflammatory pathways are chronically activated during epileptogenesis and that 
they persist in chronic epileptic tissue, suggesting that they may contribute to the 
etiopathogenesis of some types of epilepsy, such as TLE (Ravizza et al., 2008). 
4.3 Temporal lobe epilepsy (TLE) 
Temporal lobe epilepsy refers to both lesional and nonlesional epilepsies characterized by 
focal seizures arising from either the neocortex or the mesial temporal structures. One of 
these syndromes is TLE, associated with hippocampal sclerosis (HS), a histopathologic 
condition characterized by neuronal loss and gliosis, predominantly affecting the CA1 
region and the dentate gyrus. Increased IL-1┙ expression in microglia-like cells (Aronica et 
al., 2007), TLE with hippocampal sclerosis, and astroglial, microglial, and neuronal (5/8 
cases) expression of C1q, C3c, and C3d were observed, particularly within regions where 
neuronal cell loss occurs (Crespel et al., 2002). Bauer et al (2009) showed that patients with 
well-characterized TLE led to immediate and long lasting posictal increase in systemic IL-6 
levels; however this rise of IL-6 was lacking in patients with hippocampal sclerosis. The 
authors in accord with Meador et al.,(2004)  suggest the cerebral  lateralization of immune 
functions. On the other hand, there was expression of proinflammatory molecules in 
neurons and glia in brain tissue obtained from patients surgically treated for drug-resistant 
epilepsies (Crespel et al., 2002; Maldonado et al., 2003). In particular, the genes involved in 
the biological process of immunity and host defense are highly overrepresented in HS TLE 
patients; the functional gene classes most affected are chemokines and neuropeptides (De 
Simoni et al.,2000; van Gassen et al., 2008). Evaluation of immunological parameters applied 
to different groups of epileptogenic focus localization has shown that the increase of CD8+ 
lymphocytes is limited to temporal and lateralized patients. Patients with extratemporal 
localization of focus, as well as psychogenic cases, show normal levels of immunological 
lymphocyte markers (Lorigados-Pedre., 2004). Thus, upregulation of these chemokines in 
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the human TLE hippocampus may contribute not only to neuropathology, but also to 
epileptogenesis. Early up regulation of chemokines, for instance, after viral infection, may 
represent a common pathway linking the various predisposing factors in the etiology of 
TLE, such as trauma, febrile seizures, meningitis, encephalitis, and tumors.) These data 
show that specific inflammatory pathways are chronically activated during epileptogenesis 
and that they persist in chronic epileptic tissue, suggesting that they may contribute to the 
etiopathogenesis of TLE (van Gassen et al, 2008) 
4.4 Rasmussen’s encephalitis 
Rasmussen's encephalitis serves as a prototype of inflammatory epilepsy. The autoimmune 
nature of this condition was suspected after the discovery of autoantibodies against the 
glutamate receptor GluR3, one of the AMPA (ǂ-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid) subunits. Subsequently, anti-GluR3 antibodies were detected in 
other epilepsy syndromes, including early-onset noninflammatory focal epilepsy and 
catastrophic infantile epilepsy (Mantegazza et al., 2002). There is no effective medical 
treatment for Rasmussen's encephalitis, except perhaps steroids, which can be useful when 
given early in the course of the disease (Robitaille, 1991). Functional hemispherectomy has 
been the main procedure used to stop progression of the disease; in this way, the tissue 
could be examined and the progression of an inflammatory process confirmed. Pardo et al. 
(2004) describe the effect of disease duration on the burden of pathology. The greatest 
intensity of inflammation and microglial proliferation with nodule formation are generally 
seen in early states (Fig.3), followed by a decrease in the later stages. The intensity of 
inflammation, as represented by accumulation of T cells and microglial proliferation (Fig.3), 
has been reported to bear an inverse correlation with disease duration (Bauer et al., 2002; 
2007). Different stages of inflammation may coexist in the same patient with a multifocal 
distribution, which is consistent with an ongoing and progressive immune-mediated 
process (Gahring et al., 2001;Neumann et al., 2002). CD8+ T cells are located in close 
opposition to degenerating neurons and may contribute to neuronal cell death via secretion 
of granzyme B, a strong activator of caspase-mediated apoptosis (He et al., 1998; Bien et al., 
2002; 2005). Activated CD4+ T cells may also prime B cells to produce autoantibodies. The 
resulting autoantibodies may destroy neurons, either directly by excessive stimulation of 
receptor-mediated ion channels or indirectly by binding complement factors and leading to 
the formation of the MAC (Bien et al., 2002;2007) which can induce neuronal loss and 
seizures (Xiong et al., 2003). Epileptic activity may induce inflammatory mediators in 
microglia, astrocytes, neurons, and endothelial cells and may alter the properties and 
permeability of the BBB, thus facilitating the entry of components of the adaptive immune 
system and molecules usually excluded from the brain parenchyma. These phenomena may 
consolidate and perpetuate inflammatory reactions in the brain of an affected individual 
and exacerbate brain damage, thus contributing to brain atrophy. It is still unknown which 
mechanism ultimately leads to the autoimmune process: viral infection (Xiong et al., 2003), 
head trauma, or even seizures per se; knowledge of the factors that precipitate the disease 
can enable prevention of the future development of chronic epilepsy. These recent findings 
recall attention to the possibility that a viral antigen may act as the initiating event in the 
complex pathogenetic mechanism leading to brain damage in RE. A cytotoxic T-cell 
response is in fact compatible with a viral infection, and a viral infection could explain the 
peculiar hemispheric distribution with centrifugal expansion observed in RE. Previous 
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studies failed to conclusively link a specific virus to RE, but this of course does not rule out 
the possible role of an unknown virus.  
 
Fig. 3. Photomicrographs of activated microglia (HLA-Dr positive cells, green), A) nodules 
of microglia in Rasmussen syndrome, B) cortical dysplasia. Cytotoxic T lymphocytes (CD8 
+, green) in dysplasia  and TLE in (F). Coexpression in capillary of P-glycoprotein (green) 
and Cox-2 (red) in D and E in Rasmussen syndrome. (scale bar 20  µm D-F) 
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4.5 West syndrome (WS) 
WS is an age-related epileptic encephalopathy with onset in the first year of life, featuring 
clustered spasms and hypsarrhythmia. It may occur in previously healthy children 
(cryptogenic WS) but more frequently is a symptom of different congenital or acquired 
diseases (symptomatic WS). Regardless of the etiology, WS patients benefit most from 
steroid treatment. Steroid efficacy, together with the possibility of spasm disappearance 
after viral infections (Hattori, 2001), has long been considered an index for an inflammatory 
or immune-mediated pathogenesis. A recent report (You et al., 2009). of increased serum 
levels of IL-2, TNF-┙, and IFN-┙ in both cryptogenic and symptomatic WS reinforce this 
hypothesis. These cytokines are produced by monocytes and lymphocytes, and TNF-┙ is 
also produced by brain glial cells; all three have effects that may contribute to seizures and 
neuronal cell damage (Brunson et al., 1991). The presence of proinflammatory molecules in 
both cryptogenic and symptomatic WS patients suggests that cytokine changes are likely to 
be related to epilepsy rather than to the underlying etiology. However, symptomatic 
patients displayed a greater elevation of IL-2 levels, which varied depending on the 
underlying disorder (Prasad et al., 1996). If the extent of the inflammatory reaction depends 
also on the underlying disease, this could partly explain the different efficacies of steroid 
treatment in selected etiologic subgroups of symptomatic WS patients. For example, 
treatment with steroids and adrenocorticotropic hormone ACTH prevents patients with SW 
from developing Lenox-Gastau (Klein & Livingston, 1950). However, the mechanism 
underlying the anticonvulsant action of corticosteroids or ACTH remains elusive. 
Observations from animal models suggest that ACTH acts to repress infantile spasms by 
suppressing the level of endogenous corticotrophin releasing hormone (CRH) because stress 
receptors are located in areas of the brain known to be involved in seizure generation (Klein, 
1950). It is postulated that the stimulation of synthesis of glucocorticoids that interact with 
CNS steroid receptors, which then influence voltage-dependent calcium channels, 
stimulates neurosteroid synthesis in glia and neurons that modulate GABAA receptors, 
down-regulating CRH, which has pro-convulsant activity in the immature brain, and 
immunomodulation (Joels, 1991) 
4.6 Febrile seizures (FS) 
FS are the most common cause of seizures in children, affecting 2 to 5% of children. The 
threshold to febrile seizures is dependent on body temperature, but the threshold varies 
with individuals and according to age and maturation (Millichap, 1959). A genetic 
susceptibility to inflammation may influence the threshold convulsive temperature. 
Seventeen to 30% of febrile seizure patients have a family history of febrile seizures 
(Millichap, 1959).  A biallelic polymorphism in the promoter region of IL-1 at β the -511 
position that can increase IL-1β production occurs more frequently in patients with 
prolonged febrile convulsions (Virta et al., 2002; Kanemoto et al., 2003).  In experimental 
animals, intraventricular injection of IL-1β reduce the seizure threshold in 14-day old mice 
subjected to hyperthermia, while IL-1receptor knock-out mice have higher seizure 
thresholds, supporting the role of proinflammatory cytokines in triggering febrile seizures 
(Dubé et al., 2005) 
Viruses are being increasingly implicated as causative agents of febrile seizures. 
Neurotropic viruses, such as the herpesviruses and influenza A, are commonly associated 
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with febrile seizures in the United States and Asia (Hall et al., 1994; Chiu et al., 2001).  Fever 
induced by viral infection is regulated by components of the immune response, particularly 
proinflammatory cytokines. Proinflammatory cytokines are higher in influenza-associated 
febrile seizures, further suggesting a causative role for cytokines in the pathogenesis of 
febrile seizures.  
5. Anti-inflammatory treatments in epilepsy 
Nearly 30% of epilepsy patients are refractory to conventional anti-epileptic drugs, and 
many alternative treatments have been tried to control epilepsy.(Prasad et al 1996).  
Immunotherapy, such as corticosteroids and ACTH, has been used to treat epilepsy since 
ACTH was first reported to have beneficial effects in the treatment of infantile spasms in 
1950 (Klein, 1950 & Livingston,1950). For example there is no effective medical treatment for 
Rasmussen's encephalitis, except perhaps steroids,which  can be useful when given early in 
the course of the disease(Bahi-Buisson et al., 2007), A long term follow-up of 11 Rasmussen's 
encephalitis patients who received steroids showed that 45% of patients had significant 
improvement of motor function and reduction of seizure frequency with disappearance of 
epilepsia partialis continua, while 55% patients had no benefit from steroid therapy and 
ultimately underwent hemispherotomy. Two initial responders to steroid treatment 
experienced progressive recurrence of seizures one to four years after the discontinuation of 
steroids and received a hemispherotomy. ACTH is a well-known effective treatment for 
infantile spasms that not only results in seizure control, but also improves both behavior 
and background EEG (Low, 1958).  Meta-analysis reveals that ACTH is probably effective 
for short-term treatment of infantile spasms and leads to resolution of hypsarrhythmia 
(Mackay et al., 2004). Time to response is usually two weeks. Oral steroids can render 30 to 
40% of patients seizure-free (Baram et al., 1996; Hrachovy et al., 1983). Further, early use of 
steroids is more effective; patients treated within one month of spasm onset had a better 
outcome than those treated after more than one month (Lombroso et al., 1983). The 
mechanism behind the anticonvulsant action of corticosteroids or ACTH remains elusive. 
Possibilities include (1) stimulation of glucocorticoid synthesis that interacts with CNS 
steroid receptors, which then influences voltage-dependent calcium channels; (2) 
stimulation of neurosteroid synthesis in glia and neurons that modulate GABAA receptors; 
(3) down-regulation of corticotrophin releasing hormone (CRH) that has proconvulsant 
activity in the immature brain; or (4) immunomodulation (Hrachovy et al.,1994; Baram et al., 
1998; Reddy et al., 2000; Joëls, 2001). 
On the other hand, various classes of specific anti-inflammatory drugs have been studied 
using models of status epilepticus or in kindling. The outcome measures were affected 
differently by inhibition of specific inflammatory pathways depending on the experimental 
model and the treatment schedule. For example non steroidal anti-inflammatory drugs 
(NSAIDs) NSAIDs act as inhibitors of constitutive COX-1 and inducible COX-2 enzymes. 
COX-2 selective inhibitors, such as celecoxib, parecoxib and SC58236, have been used to 
interfere with status epilepticus-induced epileptogenesis that was provoked either by 
electrical stimulation or systemic injection of pilocarpine in rats. These effects were observed 
under celecoxib treatment, thus a direct anticonvulsant action of this drug cannot be 
excluded. 
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Clinical phase Drug/treatment 
Animal models or 
Seizure type 
Mechanism References 
Experimental 
(I) 
Methanolic extract of 
Asparagus pubescens 
PTZ-induced seizures Inhibits inflammation 
and seizures 
Nwafor  et 
al., 2003 
     
Experimental(I) Aqueous and 
ethanolic extract of 
Solanum nigrum 
Picrotoxin, 
pentylenetetrazole, 
and electroshocks 
induced seizures  
 
Immunomodulatory 
activity 
Jain  et al, 
2011., Ravi  et 
al., 2009 
Experimental(I) Pralnacasan or 
VX-765 
Kainic acid induced 
seizures 
 
Interleukina converting 
enzyme/caspase 1 
inhibitors and IL-1beta 
receptor antagonists 
 
Vezzani  et 
al., 2010 
Experimental(I) Naringin 
 
kainic acid-induced 
status epilepticus in 
rats 
Attenuated the  
TNF-ǂ  and 
malondialdehyde levels. 
 
Golechha et 
al, 2011 
Experimental(I) Dexamethasone Lithium and 
pilocarpine induced 
status epilepticus  
 
IL-1 type 1 receptor 
antagonist and 
reduction in the number 
of circulating T-cells 
(CD3+) 
 
Marchi  et al, 
2009 
Experimental(I) Naringin, a 
bioflavanoid 
kainic acid (KA)-
induced seizures 
Antioxidant and anti-
inflammatory activity. 
Golechha et 
al., 2011 
 
Experimental(I) SC-58236, Celecoxib electrically induced 
SE, Rat model of 
pharmacoresistant 
epilepsy 
Selective inhibition of 
cyclooxygenase-2 
Holtman  et 
al., 2010, 
Schlichtiger  
et al, 2010 
Experimental(I) Minozac Electroconvulsive 
shock 
Suppression of 
proinflammatory 
cytokine 
Somera-
Molina  et al., 
2009; 
Chrzaszcz  et 
al., 2010 
 
Phase II/III VX-765 Resistant partial 
epilepsy 
 
ICE/caspase-1 
blockade 
Clinical trials 
gov. 
In use ACTH, prednisolone, 
and prednisone 
Several epileptic 
syndromes 
Antiinflammatory 
effects 
Özkara Ç and 
Vigevano, 
2011 
In use Dexamethasone, 
methylprednisolone 
and  hydrocortisone 
West, Landau-Kleffner 
or Lennox-Gastaut 
syndromes and 
Rasmussen 
encephalitis 
 
Antiinflammatory 
effects and 
improvement 
of BBB integrity 
Marchi  et al., 
2011 
In use Vigabatrin /and 
ACTH 
Infantile spasms Interfere with the 
cellular immune 
response 
Ibrahim  et 
al., 2010 
 
Table 1. Immunotherapy  treatments  in epilepsy 
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Daily celecoxib treatment, starting 24 h post-status epilepticus for 42 days, resulted in 
reduction in the number and frequency of video-monitored spontaneous seizures (Jung, 
2006). Other COX-2 inhibitors including nimesulide and rofecoxib, nonselective COX 
inhibitors such as paracetamol, naproxen, ibuprofen,mefenamic acid and indomethacin, and 
one selective COX-1 inhibitor SC560, have been tested in the kindling model of 
epileptogenesis, induced either by repetitive PTZ injections or by electrical stimulation. A 
significant delay in stage 5 seizure acquisition (i.e. delay in kindling development) was 
shown in NSAIDs-treated animals, with the exception of ibuprofen, which was found to be 
ineffective (Tanaka et al., 2009). 
Three classical immunosuppressant agents have been used, namely cyclosporine A, FK-506 
also known as Tacrolimus, and rapamycin. Their mechanisms of action include inhibition of 
T lymphocyte activation, although rapamycin alters multiple cellular functions by inhibiting 
mTOR kinase. Daily systemic injection of cyclosporine A or FK-506 during electrical 
amygdala kindling prevented the acquisition of stage 5 seizures in rats (Moia et al., 1994 ). 
Similar effects of FK-506 were shown in PTZ mkindling in mice(Singh, 2003). However, after 
drug withdrawal, stimulated animals showed stage 5 seizures, indicating that the 
treatments failed to inhibit epileptogenesis while providing anticonvulsant effects (Moia et 
al., 1994). Opposite effects were reported by Suzuki et al. (2001), showing acceleration of 
PTZ kindling in rats treated with FK-506. The pretreatment with VID-82925" kinase inhibitor 
molecule in 4-AP induced seizures model which revealed antiepileptogenic effect and it 
significantly suppressed the manifestation of epileptiform activity and was also effective 
against ictogenesis during the stable phase of focus (Gajda et al., 2011).  Overall, these data 
indicate that the efficacy of immunosuppressant in kindling epileptogenesis is still 
controversial and requires further investigation, possibly using similar treatment protocols 
in the same kindling models. More consistent data are obtained in models of status 
epilepticus-induced epileptogenesis where T-cells do not appear to play a major role. Future 
studies are needed to target specific molecules involved in some of the pathways of the 
inflammatory process and to reduce adverse effects. 
6. Concluding remarks 
Accumulating evidence suggests that inflammatory and immune reactions may play an 
important role in promoting increased neuronal excitability, decreasing seizure threshold 
and is likely to be involved in the molecular, structural and synaptic changes characterizing 
epileptogenesis. Also, brain inflammation may contribute to the intractability of seizures 
and comorbidity in chronic epilepsy patients. Histologic analysis of the human brain from 
individuals with epilepsy of various etiologies strongly suggests the existence of a chronic 
inflammatory state in the brain almost invariably associated with neuronal loss, reactive 
gliosis, and activation of microglia. This observation, together with reports that anti-
inflammatory drugs have anticonvulsant efficacy in some cases of drug-refractory 
epilepsies, suggests the possibility that chronic inflammation in the brain may be implicated 
in the etiopathogenesis of seizures and the associated long-term events. This hypothesis is 
supported by functional studies in experimental models of seizures, showing that some 
proinflammatory molecules exacerbate seizures, decrease the threshold for inducing 
convulsions, or cause seizures, per se. 
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Anti-inflammatory therapy may be particularly helpful when given during the latency 
period shortly after the initial neurologic insult, but prior to the onset of epilepsy, before 
permanent changes can occur in the neuronal aggregates that promote hyperexcitability and 
seizure spread. It is necessary to confirm with laboratory tests in serum and blood–
cerebrospinal fluid to know the immune response of the epilepsy patient to give 
pharmacological therapy when the immune response is exacerbated. The causative role of 
inflammation in the pathogenesis of chronic intractable epilepsy needs to be established and 
requires further investigation from both the clinical and basic sciences. Pharmacological 
experiments in animal models suggest that antiepileptogenic effects might be achieved by 
interfering with specific pro-inflammatory pathways post-injury, although further studies 
are required to characterize the best targets and protocols for successful pharmacological 
intervention with limited side-effects. 
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